JP2017506513A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017506513A5 JP2017506513A5 JP2016551764A JP2016551764A JP2017506513A5 JP 2017506513 A5 JP2017506513 A5 JP 2017506513A5 JP 2016551764 A JP2016551764 A JP 2016551764A JP 2016551764 A JP2016551764 A JP 2016551764A JP 2017506513 A5 JP2017506513 A5 JP 2017506513A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- seq
- item
- vector
- items
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461940339P | 2014-02-14 | 2014-02-14 | |
| US61/940,339 | 2014-02-14 | ||
| PCT/US2015/016057 WO2015123642A1 (en) | 2014-02-14 | 2015-02-16 | Chimeric antigen receptors and methods of making |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019235725A Division JP2020058380A (ja) | 2014-02-14 | 2019-12-26 | キメラ抗原受容体及びその製造方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017506513A JP2017506513A (ja) | 2017-03-09 |
| JP2017506513A5 true JP2017506513A5 (enExample) | 2018-03-08 |
| JP6640726B2 JP6640726B2 (ja) | 2020-02-05 |
Family
ID=53800695
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016551764A Expired - Fee Related JP6640726B2 (ja) | 2014-02-14 | 2015-02-16 | キメラ抗原受容体及びその製造方法 |
| JP2019235725A Withdrawn JP2020058380A (ja) | 2014-02-14 | 2019-12-26 | キメラ抗原受容体及びその製造方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019235725A Withdrawn JP2020058380A (ja) | 2014-02-14 | 2019-12-26 | キメラ抗原受容体及びその製造方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US10125193B2 (enExample) |
| EP (2) | EP3656864A1 (enExample) |
| JP (2) | JP6640726B2 (enExample) |
| KR (1) | KR102375998B1 (enExample) |
| CN (2) | CN106414748B (enExample) |
| AU (2) | AU2015218239B2 (enExample) |
| CA (2) | CA3190002A1 (enExample) |
| DK (1) | DK3105335T3 (enExample) |
| ES (1) | ES2764471T3 (enExample) |
| IL (3) | IL247208B (enExample) |
| MX (2) | MX369513B (enExample) |
| RU (2) | RU2021123419A (enExample) |
| SG (2) | SG10201811816RA (enExample) |
| WO (1) | WO2015123642A1 (enExample) |
| ZA (2) | ZA201605655B (enExample) |
Families Citing this family (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014117121A1 (en) | 2013-01-28 | 2014-07-31 | St. Jude Children's Research Hospital, Inc. | A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease |
| EP3974520A1 (en) | 2013-05-14 | 2022-03-30 | Board of Regents, The University of Texas System | Human application of engineered chimeric antigen receptor (car) t-cells |
| WO2014190273A1 (en) | 2013-05-24 | 2014-11-27 | Board Of Regents, The University Of Texas System | Chimeric antigen receptor-targeting monoclonal antibodies |
| CA3190002A1 (en) | 2014-02-14 | 2015-08-20 | Board Of Regents, The University Of Texas System | Chimeric antigen receptors and methods of making |
| AU2015243849B2 (en) | 2014-04-10 | 2020-12-17 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Transgene genetic tags and methods of use |
| KR102211120B1 (ko) | 2014-05-15 | 2021-02-03 | 내셔널 유니버시티 오브 싱가포르 | 변형된 천연 살해 세포 및 그의 용도 |
| GB201506423D0 (en) | 2015-04-15 | 2015-05-27 | Tc Biopharm Ltd | Gamma delta T cells and uses thereof |
| WO2016073629A1 (en) | 2014-11-05 | 2016-05-12 | Board Of Regents, The University Of Texas System | Chimeric antigen receptors (car) to selectively target protein complexes |
| KR20170075785A (ko) | 2014-11-05 | 2017-07-03 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 유전자 변형된 면역 효과기 세포 및 면역 효과기 세포의 증식용 가공된 세포 |
| WO2016138034A1 (en) | 2015-02-24 | 2016-09-01 | The Regents Of The University Of California | Binding-triggered transcriptional switches and methods of use thereof |
| EP3804741A3 (en) | 2015-02-24 | 2021-07-14 | Board of Regents, The University of Texas System | Selection methods for genetically-modified t cells |
| CA2977818A1 (en) | 2015-03-11 | 2016-09-15 | Board Of Regents, The University Of Texas System | Transposase polypeptides and uses thereof |
| US9777064B2 (en) | 2015-03-17 | 2017-10-03 | Chimera Bioengineering, Inc. | Smart CAR devices, DE CAR polypeptides, side CARs and uses thereof |
| ES2988584T3 (es) * | 2015-04-23 | 2024-11-21 | Baylor College Medicine | Subconjunto de células NKT para persistencia y actividad terapéutica in vivo y propagación del mismo |
| GB201507368D0 (en) | 2015-04-30 | 2015-06-17 | Ucl Business Plc | Cell |
| BR112017024757A2 (pt) | 2015-05-18 | 2018-11-13 | TCR2 Therapeutics Inc. | composições e métodos para reprogramação de tcr utilizando proteínas de fusão |
| US11116795B2 (en) | 2015-07-10 | 2021-09-14 | The Trustees Of The University Of Pennsylvania | Treatment of a canine CD20 positive disease or condition using a canine CD20-specific chimeric antigen receptor |
| JP7162530B2 (ja) | 2015-08-07 | 2022-10-28 | シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） | 固形腫瘍を標的とする二重特異性ｃａｒ ｔ細胞 |
| CN114657173A (zh) * | 2015-09-01 | 2022-06-24 | 加利福尼亚大学董事会 | 模块化多肽文库以及其制备和使用方法 |
| KR20180042449A (ko) | 2015-09-15 | 2018-04-25 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | T 세포 수용체(tcr) 결합 항체 및 이의 용도 |
| EP3368075B1 (en) | 2015-10-27 | 2020-01-29 | Board of Regents, The University of Texas System | Chimeric antigen receptor molecules and uses thereof |
| US11052111B2 (en) | 2015-12-08 | 2021-07-06 | Chimera Bioengineering, Inc. | Smart CAR devices and DE CAR polypeptides for treating disease and methods for enhancing immune responses |
| US11400116B2 (en) | 2016-05-06 | 2022-08-02 | The Regents Of The University Of California | Systems and methods for targeting cancer cells |
| US10222369B2 (en) | 2016-05-17 | 2019-03-05 | Chimera Bioengineering, Inc. | Methods for making novel antigen binding domains |
| EP3468994A1 (en) | 2016-06-08 | 2019-04-17 | Intrexon Corporation | Cd33 specific chimeric antigen receptors |
| CN106167527A (zh) * | 2016-06-13 | 2016-11-30 | 长沙郝怡雅医药科技有限公司 | 一种融合蛋白 |
| EP3263595A1 (en) * | 2016-06-30 | 2018-01-03 | Medizinische Hochschule Hannover | Fusion protein for use in the treatment of hvg disease |
| EP3714944A1 (en) | 2019-03-29 | 2020-09-30 | Medizinische Hochschule Hannover | Car for use in the treatment of hvg disease |
| WO2018026953A1 (en) | 2016-08-02 | 2018-02-08 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| KR102637610B1 (ko) | 2016-08-23 | 2024-02-19 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 단백질용해 절단가능한 키메라 폴리펩타이드 및 이의 사용 방법 |
| EP4342978A3 (en) | 2016-09-01 | 2024-07-03 | Chimera Bioengineering Inc. | Gold optimized car t-cells |
| RU2019112860A (ru) * | 2016-09-27 | 2020-10-30 | Серо Терапьютикс, Инк. | Молекулы химерных интернализационных рецепторов |
| US20190119636A1 (en) * | 2017-10-23 | 2019-04-25 | Poseida Therapeutics, Inc. | Modified stem cell memory t cells, methods of making and methods of using same |
| MX2019003899A (es) | 2016-10-07 | 2019-08-14 | Tcr2 Therapeutics Inc | Composiciones y metodos para reprogramacion de receptores de linfocitos t mediante el uso de proteinas de fusion. |
| AU2017363311A1 (en) | 2016-11-22 | 2019-06-13 | TCR2 Therapeutics Inc. | Compositions and methods for TCR reprogramming using fusion proteins |
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| WO2018182511A1 (en) | 2017-03-27 | 2018-10-04 | National University Of Singapore | Stimulatory cell lines for ex vivo expansion and activation of natural killer cells |
| IL269553B2 (en) | 2017-03-27 | 2025-10-01 | Nat Univ Singapore | Truncated NKG2D chimeric receptors and their uses in immunotherapy with natural killer cells |
| CN107177632B (zh) * | 2017-05-27 | 2020-02-07 | 上海优卡迪生物医药科技有限公司 | 一种基于octs技术的髓系白血病car-t治疗载体及其构建方法和应用 |
| AU2018281316B2 (en) | 2017-06-07 | 2024-05-30 | Precigen, Inc. | Expression of novel cell tags |
| CN109337872B (zh) * | 2017-07-27 | 2023-06-23 | 上海细胞治疗研究院 | 高效扩增car-t细胞的人工抗原递呈细胞及其用途 |
| CN107529550A (zh) * | 2017-08-28 | 2018-01-02 | 马晓冬 | 一种基于PiggyBac载体的CD‑19‑CAR‑T系统构建方法 |
| US12385061B2 (en) | 2017-09-08 | 2025-08-12 | Poseida Therapeutics, Inc. | Compositions and methods for chimeric ligand receptor (CLR)-mediated conditional gene expression |
| CA3075915A1 (en) * | 2017-09-15 | 2019-03-21 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-cd19 immunotherapy |
| AU2018341244A1 (en) * | 2017-09-26 | 2020-03-05 | Cero Therapeutics, Inc. | Chimeric engulfment receptor molecules and methods of use |
| MA50651A (fr) * | 2017-09-29 | 2020-08-05 | Us Health | Récepteurs de lymphocytes t reconnaissant p53 mutée |
| IL273961B2 (en) * | 2017-10-18 | 2025-04-01 | Precigen Inc | Polypeptide compositions containing spacers |
| US10329543B2 (en) * | 2017-10-23 | 2019-06-25 | Poseida Therapeutics, Inc. | Modified stem cell memory T cells, methods of making and methods of using same |
| SG11202003849VA (en) * | 2017-10-31 | 2020-05-28 | Allogene Therapeutics Inc | Methods and compositions for dosing of allogeneic chimeric antigen receptor t cells |
| JP7448903B2 (ja) | 2017-11-03 | 2024-03-13 | レンティジェン・テクノロジー・インコーポレイテッド | 抗ｒｏｒ１免疫療法によってがんを処置するための組成物および方法 |
| KR20250048610A (ko) | 2017-12-22 | 2025-04-09 | 페이트 세러퓨틱스, 인코포레이티드 | 향상된 면역 효과기 세포 및 이의 용도 |
| CN109970864A (zh) * | 2017-12-28 | 2019-07-05 | 上海细胞治疗研究院 | 一种双向激活共刺激分子受体及其用途 |
| CA3086832A1 (en) | 2018-01-03 | 2019-07-11 | Qu Biologics Inc. | Innate targeting of adoptive cellular therapies |
| CN111801348A (zh) | 2018-02-09 | 2020-10-20 | 新加坡国立大学 | 活化性嵌合受体及其在自然杀伤细胞免疫疗法中的用途 |
| CN111989108B (zh) | 2018-02-13 | 2024-07-16 | 嵌合体生物工程公司 | 利用rna去稳定元件协调基因表达 |
| WO2019178518A1 (en) * | 2018-03-16 | 2019-09-19 | The Regents Of The University Of California | Cellular signaling domain engineering in chimeric antigen receptor-modified regulatory t cells |
| EP3774865A1 (en) * | 2018-03-28 | 2021-02-17 | Cero Therapeutics, Inc. | Cellular immunotherapy compositions and uses thereof |
| WO2019191334A1 (en) * | 2018-03-28 | 2019-10-03 | Cero Therapeutics, Inc. | Chimeric tim4 receptors and uses thereof |
| WO2019191495A1 (en) | 2018-03-29 | 2019-10-03 | Fate Therapeutics, Inc. | Engineered immune effector cells and use thereof |
| SG11202008976YA (en) | 2018-04-02 | 2020-10-29 | Nat Univ Singapore | Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells |
| CN110577605A (zh) * | 2018-06-11 | 2019-12-17 | 浙江启新生物技术有限公司 | 一种靶向多发性骨髓瘤多种抗原的嵌合抗原受体t（car-t）细胞的构建方法及其应用 |
| CN110850068B (zh) * | 2018-08-21 | 2023-08-15 | 上海恒润达生生物科技股份有限公司 | 一种嵌合抗原受体亲和力检测方法 |
| EP3844186A4 (en) | 2018-08-29 | 2022-08-17 | National University of Singapore | METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS |
| CA3120563A1 (en) | 2018-11-26 | 2020-06-04 | Nkarta, Inc. | Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy |
| SG11202105480WA (en) | 2018-12-02 | 2021-06-29 | Fate Therapeutics Inc | IMMUNOTHERAPIES USING ENHANCED iPSC DERIVED EFFECTOR CELLS |
| CN111253487B (zh) * | 2018-12-03 | 2024-02-02 | 广东东阳光药业股份有限公司 | Cd19抗体及其应用 |
| US11793834B2 (en) | 2018-12-12 | 2023-10-24 | Kite Pharma, Inc. | Chimeric antigen and T cell receptors and methods of use |
| CN109777784B (zh) * | 2019-02-22 | 2021-12-31 | 上海尚泰生物技术有限公司 | 一种增强向肿瘤部位迁移的嵌合抗原受体载体构建方法与应用 |
| WO2020180882A1 (en) | 2019-03-05 | 2020-09-10 | Nkarta, Inc. | Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy |
| US20200325241A1 (en) * | 2019-04-11 | 2020-10-15 | Massachusetts Institute Of Technology | Novel chimeric antigen receptors and libraries |
| EP4013431A4 (en) | 2019-08-18 | 2024-05-01 | Chimera Bioengineering, Inc. | Combination therapy with gold controlled transgenes |
| KR20220097875A (ko) | 2019-09-03 | 2022-07-08 | 마이얼로이드 테라퓨틱스, 인크. | 게놈 통합을 위한 방법 및 조성물 |
| MX2022002747A (es) | 2019-09-10 | 2022-04-06 | Obsidian Therapeutics Inc | Proteinas de fusion de ca2-il15 para regulacion ajustable. |
| GB201915384D0 (en) * | 2019-10-23 | 2019-12-04 | Ucl Business Ltd | Vector |
| CN111304244A (zh) * | 2019-11-13 | 2020-06-19 | 沣潮医药科技（上海）有限公司 | 携带基因元件组合的载体组件、受体细胞文库、制备和筛选方法及用途 |
| CN110964750A (zh) * | 2019-11-13 | 2020-04-07 | 沣潮医药科技（上海）有限公司 | 携带基因元件组合的嵌合抗原受体细胞文库、制备和筛选方法及用途 |
| IL294715A (en) | 2020-01-23 | 2022-09-01 | Childrens Medical Ct Corp | Stroma-free t cell differentiation from human pluripotent stem cells |
| WO2021217087A1 (en) | 2020-04-23 | 2021-10-28 | The Regents Of The University Of California | Genetically engineered phagocytes, and related compositions, vectors, methods and systems |
| IL298558A (en) | 2020-05-27 | 2023-01-01 | Antion Biosciences Sa | Adapter molecules redirect CAR T cells to the antigen of interest |
| GB202008688D0 (en) * | 2020-06-09 | 2020-07-22 | Cancer Research Tech Ltd | Chimeric antigen receptor cell |
| MX2022015863A (es) | 2020-06-19 | 2023-03-23 | Fate Therapeutics Inc | Combinación de tipos de células efectoras derivadas de células madre pluripotentes inducidas (ipsc) para uso en inmunoterapia. |
| CN113913458A (zh) * | 2020-07-09 | 2022-01-11 | 杭州优凯瑞医药科技有限公司 | 非病毒方法制备稳定高表达嵌合受体的nk细胞 |
| CN112062859B (zh) * | 2020-07-24 | 2022-08-09 | 沣潮医药科技（上海）有限公司 | 用于病原体清除的嵌合抗原受体及其应用 |
| US20240067955A1 (en) | 2021-01-20 | 2024-02-29 | Coding Bio Limited | Methods for high throughput screening of chimeric antigen receptors |
| JP2024515662A (ja) * | 2021-04-23 | 2024-04-10 | ソレント・セラピューティクス・インコーポレイテッド | Ｇｄ２に結合する二量体抗原受容体（ｄａｒ） |
| BR112023023642A2 (pt) | 2021-05-11 | 2024-01-30 | Myeloid Therapeutics Inc | Métodos e composições para integração genômica |
| WO2023056194A2 (en) | 2021-09-29 | 2023-04-06 | Chimera Bioengineering, Inc. | Compositions and methods for anti-tnmuc1 gold car t-cells |
| US20250135002A1 (en) * | 2022-02-04 | 2025-05-01 | Duke University | Compositions for and method of effecting tumor cell death |
| US20250136689A1 (en) * | 2022-02-04 | 2025-05-01 | Duke University | Compositions for and methods of treating hematological cancers |
| KR20250005097A (ko) | 2022-04-08 | 2025-01-09 | 페이트 세러퓨틱스, 인코포레이티드 | 고형 종양 표적화 골격을 갖는 세포 및 이의 용도 |
| JP7707304B2 (ja) | 2022-04-08 | 2025-07-14 | フェイト セラピューティクス，インコーポレイティド | 腫瘍標的化のためのキメラ抗原受容体 |
| JPWO2024150828A1 (enExample) * | 2023-01-12 | 2024-07-18 |
Family Cites Families (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
| US8211422B2 (en) | 1992-03-18 | 2012-07-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric receptor genes and cells transformed therewith |
| EP0814838B1 (en) | 1995-03-08 | 2003-05-14 | The Scripps Research Institute | Antigen presenting system and activation of t-cells |
| AU723355B2 (en) | 1996-05-23 | 2000-08-24 | Scripps Research Institute, The | MHC class II antigen presenting systems and methods for activating CD4+ T cells |
| EP0973928B1 (en) | 1997-03-11 | 2010-05-05 | Regents Of The University Of Minnesota | Dna-based transposon system for the introduction of nucleic acid into dna of a cell |
| EP0972039A1 (en) | 1997-03-25 | 2000-01-19 | Morphogenesis, Inc. | Universal stem cells |
| AU2472400A (en) | 1998-10-20 | 2000-05-08 | City Of Hope | CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies |
| US6790662B1 (en) | 1999-03-12 | 2004-09-14 | Ortho-Mcneil Pharmaceutical, Inc. | Method of isolating CD8+ cells, and related hybridoma cells antibodies and polypeptides |
| AU2001297703B2 (en) * | 2000-11-07 | 2006-10-19 | City Of Hope | CD19-specific redirected immune cells |
| US20040071671A1 (en) | 2001-02-20 | 2004-04-15 | Leturcq Didier J. | Cell therapy method for the treatment of tumors |
| US20030157561A1 (en) | 2001-11-19 | 2003-08-21 | Kolkman Joost A. | Combinatorial libraries of monomer domains |
| CA2445746C (en) | 2001-04-30 | 2012-09-18 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| CA2476006A1 (en) | 2002-02-05 | 2003-08-14 | Japan Science And Technology Agency | Egf/egfr complex |
| US20030194704A1 (en) | 2002-04-03 | 2003-10-16 | Penn Sharron Gaynor | Human genome-derived single exon nucleic acid probes useful for gene expression analysis two |
| US8227432B2 (en) | 2002-04-22 | 2012-07-24 | Regents Of The University Of Minnesota | Transposon system and methods of use |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| JP2009523404A (ja) | 2003-01-30 | 2009-06-25 | アプレラ コーポレイション | 慢性関節リウマチに関連する遺伝的多型、その検出方法および使用 |
| US8802643B1 (en) | 2003-05-30 | 2014-08-12 | University Of South Florida | Method for the treatment of malignancies |
| NZ570709A (en) | 2003-06-13 | 2010-04-30 | Univ Pennsylvania | Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same |
| US7109304B2 (en) | 2003-07-31 | 2006-09-19 | Immunomedics, Inc. | Humanized anti-CD19 antibodies |
| US7888121B2 (en) | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
| WO2005019420A2 (en) * | 2003-08-20 | 2005-03-03 | St. Jude Children's Research Hospital | Chimeric receptors with disrupted dileucine motifs |
| US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
| US20130266551A1 (en) * | 2003-11-05 | 2013-10-10 | St. Jude Children's Research Hospital, Inc. | Chimeric receptors with 4-1bb stimulatory signaling domain |
| US20050113564A1 (en) | 2003-11-05 | 2005-05-26 | St. Jude Children's Research Hospital | Chimeric receptors with 4-1BB stimulatory signaling domain |
| CA2590401C (en) | 2004-10-08 | 2015-04-21 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Adoptive immunotherapy with enhanced t lymphocyte survival |
| PL1899364T5 (pl) | 2005-05-17 | 2024-12-09 | University Of Connecticut | Kompozycje i sposoby immunomodulacji w organizmie |
| WO2007014275A2 (en) | 2005-07-26 | 2007-02-01 | Sangamo Biosciences, Inc. | Targeted integration and expression of exogenous nucleic acid sequences |
| US20070036773A1 (en) | 2005-08-09 | 2007-02-15 | City Of Hope | Generation and application of universal T cells for B-ALL |
| EP1777294A1 (en) | 2005-10-20 | 2007-04-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins |
| US7993638B2 (en) | 2006-03-01 | 2011-08-09 | Janssen Pharmaceutica Nv | Cancer treatment combining lymphodepleting agent with CTLs and cytokines |
| US20070283453A1 (en) | 2006-05-31 | 2007-12-06 | Juan Carlos Rodriguez Cimadevilla | Animal models of tumor metastasis and toxicity |
| RU2355763C2 (ru) | 2006-09-13 | 2009-05-20 | Закрытое акционерное общество "Научно-исследовательский институт Аджиномото-Генетика" (ЗАО АГРИ) | Мутантная ацетолактатсинтаза и способ продукции разветвленных l-аминокислот |
| CA2665568C (en) | 2006-10-04 | 2018-01-09 | Janssen Pharmaceutica, N.V. | Preparation of inactivated artificial antigen presenting cells and their use in cell therapies |
| ZA200902346B (en) * | 2006-10-12 | 2010-07-28 | Genentech Inc | Antibodies to lymphotoxin-alpha |
| PL2856876T3 (pl) | 2007-03-30 | 2018-06-29 | Memorial Sloan-Kettering Cancer Center | Konstytutywna ekspresja ligandów kostymulujących na limfocytach T poddanych transferowi adoptywnemu |
| CA2691785C (en) | 2007-06-27 | 2017-01-10 | Marine Polymer Technologies Inc. | Complexes of il-15 and il-15ralpha and uses thereof |
| WO2009091826A2 (en) | 2008-01-14 | 2009-07-23 | The Board Of Regents Of The University Of Texas System | Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car) |
| US20100105140A1 (en) | 2008-07-16 | 2010-04-29 | Fahrenkrug Scott C | Plaice dna transposon system |
| CA2736851A1 (en) | 2008-09-11 | 2010-03-18 | Lung-Ji Chang | System and method for producing t cells |
| SG10201402742YA (en) | 2009-03-20 | 2014-08-28 | Genentech Inc | Bispecific anti-her antibodies |
| US8465743B2 (en) | 2009-10-01 | 2013-06-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer |
| WO2011059836A2 (en) | 2009-10-29 | 2011-05-19 | Trustees Of Dartmouth College | T cell receptor-deficient t cell compositions |
| US8956828B2 (en) | 2009-11-10 | 2015-02-17 | Sangamo Biosciences, Inc. | Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases |
| WO2011159847A2 (en) | 2010-06-15 | 2011-12-22 | The Regents Of The University Of California | Receptor tyrosine kinase-like orphan receptor 1 (ror1) single chain fv antibody fragment conjugates and methods of use thereof |
| CA3157027A1 (en) | 2010-07-21 | 2012-01-26 | Sangamo Therapeutics, Inc. | Methods and compositions for modification of a t-cell receptor gene |
| EP2619229B1 (en) | 2010-09-21 | 2016-04-06 | Altor BioScience Corporation | Multimeric il-15 soluble fusion molecules and methods of making and using same |
| PH12013501201A1 (en) * | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| US9402865B2 (en) * | 2011-01-18 | 2016-08-02 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treating cancer |
| US10421960B2 (en) | 2011-09-16 | 2019-09-24 | The Trustees Of The University Of Pennsylvania | RNA engineered T cells for the treatment of cancer |
| US9708384B2 (en) * | 2011-09-22 | 2017-07-18 | The Trustees Of The University Of Pennsylvania | Universal immune receptor expressed by T cells for the targeting of diverse and multiple antigens |
| IN2014CN02906A (enExample) | 2011-10-20 | 2015-07-03 | Us Health | |
| US9272002B2 (en) * | 2011-10-28 | 2016-03-01 | The Trustees Of The University Of Pennsylvania | Fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting |
| JP6117515B2 (ja) * | 2011-11-01 | 2017-04-19 | 国立大学法人名古屋大学 | 髄膜腫治療用医薬組成物 |
| WO2013074916A1 (en) * | 2011-11-18 | 2013-05-23 | Board Of Regents, The University Of Texas System | Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla |
| KR102083957B1 (ko) | 2011-12-05 | 2020-03-04 | 노파르티스 아게 | 표피 성장 인자 수용체 3 (her3)에 대한 항체 |
| KR20140127816A (ko) * | 2012-02-22 | 2014-11-04 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 암의 치료에 유용한 t 세포의 지속성 집단을 생성시키기 위한 조성물 및 방법 |
| SG11201404769UA (en) * | 2012-02-22 | 2014-11-27 | Univ Pennsylvania | Use of icos-based cars to enhance antitumor activity and car persistence |
| ES3065694T3 (en) | 2012-04-11 | 2026-05-07 | Us Health | Chimeric antigen receptors targeting b-cell maturation antigen |
| US20130280220A1 (en) | 2012-04-20 | 2013-10-24 | Nabil Ahmed | Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes |
| EP4541818A3 (en) * | 2012-05-25 | 2025-07-23 | Cellectis | Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy |
| US9719066B2 (en) | 2012-09-07 | 2017-08-01 | Biolamina Ab | Stem cell bank |
| AU2013204922B2 (en) | 2012-12-20 | 2015-05-14 | Celgene Corporation | Chimeric antigen receptors |
| HK1220614A1 (zh) | 2013-03-10 | 2017-05-12 | Baylor College Of Medicine | 耐化疗免疫细胞 |
| US9657105B2 (en) * | 2013-03-15 | 2017-05-23 | City Of Hope | CD123-specific chimeric antigen receptor redirected T cells and methods of their use |
| EP3974520A1 (en) * | 2013-05-14 | 2022-03-30 | Board of Regents, The University of Texas System | Human application of engineered chimeric antigen receptor (car) t-cells |
| WO2014190273A1 (en) | 2013-05-24 | 2014-11-27 | Board Of Regents, The University Of Texas System | Chimeric antigen receptor-targeting monoclonal antibodies |
| CN105848484A (zh) | 2013-10-25 | 2016-08-10 | 得克萨斯州大学系统董事会 | 用于免疫治疗的多克隆γδ T细胞 |
| CA3190002A1 (en) | 2014-02-14 | 2015-08-20 | Board Of Regents, The University Of Texas System | Chimeric antigen receptors and methods of making |
| EP3593812A3 (en) | 2014-03-15 | 2020-05-27 | Novartis AG | Treatment of cancer using chimeric antigen receptor |
| US20170158749A1 (en) | 2014-04-23 | 2017-06-08 | Board Of Regents, The University Of Texas System | Chimeric antigen receptors (car) and methods for making and using the same |
| WO2015164740A1 (en) | 2014-04-24 | 2015-10-29 | Board Of Regents, The University Of Texas System | Application of induced pluripotent stem cells to generate adoptive cell therapy products |
| KR102211120B1 (ko) | 2014-05-15 | 2021-02-03 | 내셔널 유니버시티 오브 싱가포르 | 변형된 천연 살해 세포 및 그의 용도 |
| WO2016018920A1 (en) | 2014-07-29 | 2016-02-04 | Admune Therapeutics Llc | Il-15 and il-15ralpha heterodimer dose escalation regimens for treating conditions |
| WO2016073629A1 (en) | 2014-11-05 | 2016-05-12 | Board Of Regents, The University Of Texas System | Chimeric antigen receptors (car) to selectively target protein complexes |
| KR20170075785A (ko) | 2014-11-05 | 2017-07-03 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 유전자 변형된 면역 효과기 세포 및 면역 효과기 세포의 증식용 가공된 세포 |
| EP3804741A3 (en) | 2015-02-24 | 2021-07-14 | Board of Regents, The University of Texas System | Selection methods for genetically-modified t cells |
| CA2977818A1 (en) | 2015-03-11 | 2016-09-15 | Board Of Regents, The University Of Texas System | Transposase polypeptides and uses thereof |
| KR20180042449A (ko) | 2015-09-15 | 2018-04-25 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | T 세포 수용체(tcr) 결합 항체 및 이의 용도 |
| AU2016326575A1 (en) | 2015-09-25 | 2018-04-12 | Altor Bioscience Corporation | Interleukin-15 superagonist significantly enhances graft-versus-tumor activity |
| EP3368075B1 (en) | 2015-10-27 | 2020-01-29 | Board of Regents, The University of Texas System | Chimeric antigen receptor molecules and uses thereof |
| WO2017177063A1 (en) | 2016-04-06 | 2017-10-12 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of heterodimeric il-15 in adoptive cell transfer |
| CA3049652A1 (en) * | 2017-01-10 | 2018-07-19 | Intrexon Corporation | Modulating expression of polypeptides via new gene switch expression systems |
-
2015
- 2015-02-16 CA CA3190002A patent/CA3190002A1/en active Pending
- 2015-02-16 CA CA2938887A patent/CA2938887C/en active Active
- 2015-02-16 SG SG10201811816RA patent/SG10201811816RA/en unknown
- 2015-02-16 RU RU2021123419A patent/RU2021123419A/ru unknown
- 2015-02-16 KR KR1020167024697A patent/KR102375998B1/ko not_active Expired - Fee Related
- 2015-02-16 US US15/118,245 patent/US10125193B2/en active Active
- 2015-02-16 ES ES15749056T patent/ES2764471T3/es active Active
- 2015-02-16 EP EP19200716.9A patent/EP3656864A1/en not_active Withdrawn
- 2015-02-16 CN CN201580017207.2A patent/CN106414748B/zh not_active Expired - Fee Related
- 2015-02-16 CN CN202110505479.4A patent/CN113234757B/zh active Active
- 2015-02-16 RU RU2016136370A patent/RU2753965C2/ru active
- 2015-02-16 SG SG11201606664UA patent/SG11201606664UA/en unknown
- 2015-02-16 EP EP15749056.6A patent/EP3105335B1/en active Active
- 2015-02-16 AU AU2015218239A patent/AU2015218239B2/en not_active Ceased
- 2015-02-16 MX MX2016010566A patent/MX369513B/es active IP Right Grant
- 2015-02-16 DK DK15749056.6T patent/DK3105335T3/da active
- 2015-02-16 JP JP2016551764A patent/JP6640726B2/ja not_active Expired - Fee Related
- 2015-02-16 WO PCT/US2015/016057 patent/WO2015123642A1/en not_active Ceased
-
2016
- 2016-08-10 IL IL247208A patent/IL247208B/en active IP Right Grant
- 2016-08-12 MX MX2019009295A patent/MX2019009295A/es unknown
- 2016-08-16 ZA ZA2016/05655A patent/ZA201605655B/en unknown
-
2018
- 2018-09-28 US US16/145,790 patent/US20190085079A1/en not_active Abandoned
- 2018-11-16 ZA ZA2018/07750A patent/ZA201807750B/en unknown
-
2019
- 2019-04-10 AU AU2019202514A patent/AU2019202514B2/en not_active Ceased
- 2019-12-26 JP JP2019235725A patent/JP2020058380A/ja not_active Withdrawn
-
2020
- 2020-01-26 IL IL272264A patent/IL272264B/en active IP Right Grant
-
2021
- 2021-02-26 US US17/187,074 patent/US12065490B2/en active Active
- 2021-03-25 IL IL281819A patent/IL281819B2/en unknown
-
2024
- 2024-07-05 US US18/764,962 patent/US20250002579A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2016136370A (ru) | Химерные антигенные рецепторы и способы их получения | |
| Nigro et al. | NK-mediated antibody-dependent cell-mediated cytotoxicity in solid tumors: biological evidence and clinical perspectives | |
| AU2014228962B2 (en) | Multimerization technologies | |
| JP2019513347A5 (enExample) | ||
| CA3113409A1 (en) | Dual acting cd1d immunoglobulin | |
| JP2015527070A5 (enExample) | ||
| CN107880128B (zh) | 一种抗cd19的全人源抗体或抗体片段及其方法和应用 | |
| JP2018529327A5 (enExample) | ||
| CN112028996A (zh) | 靶向bcma的单域抗体及其用途 | |
| US20210284729A1 (en) | Genetic modified pluri- or multipotent stem cells and uses thereof | |
| RU2017121115A (ru) | Генетически модифицированные гамма дельта т-клетки | |
| JP2016537966A (ja) | 分子 | |
| JP2017514471A5 (enExample) | ||
| JP2025508050A (ja) | Ｃｄ７０指向性がん免疫療法のための多重遺伝子編集細胞 | |
| WO2020068702A1 (en) | Chimeric receptor proteins and uses thereof | |
| CN114025774A (zh) | 可切换嵌合抗原受体工程化的人自然杀伤细胞 | |
| CN117004604A (zh) | 一种ciita基因被敲除的工程化免疫细胞及其用途 | |
| CN118891290A (zh) | 细胞免疫疗法的组合物和方法 | |
| JP2024531910A5 (enExample) | ||
| CN115873801A (zh) | 工程化免疫细胞及其用途 | |
| WO2022020945A1 (en) | Anti-cd22 single domain antibodies and therapeutic constructs | |
| WO2025213573A1 (zh) | 细胞免疫疗法的组合物和方法 | |
| AU2024276506A1 (en) | Immune effector cell and use thereof | |
| WO2023016284A1 (zh) | 工程化免疫细胞及其用途 | |
| CN121194791A (zh) | 免疫细胞联合疗法 |